In Brief: Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Medtronic: Receives FDA go-ahead to market its Jewel Plus Active Can (Model 7220C) implantable-cardioverter-defibrillator, the company announces May 10. The 34-joule device incorporates Medtronic's Flashback memory feature, which Medtronic says "provides key information about the history and onset of tachyarrhythmia episodes," and the firm's Marker Channel technology, which "aids precise diagnosis by indicating device response." In addition, the device features a "new interval plotting capability (graphic display of episode characteristics) for stored tachyarrhythmia episodes," the firm says. Medtronic also releases commercially its Transvene tined silicone lead (Model 6934S), which it says is the "world's first tachyarrhythmia lead employing a steroid-eluting electrode to minimize scar-tissue formation at the endocardial wall and thus enhance sensing performance"...
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.